Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Incidence trends of pediatric psoriasis in 1990-2021: findings from the Global Burden of Disease Study 2021.
Clin Exp Dermatol
January 2025
Department of Dermatology, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Background: Pediatric psoriasis is a chronic inflammatory skin disease that poses unique challenges in diagnosis and management. While studies from high-income countries have reported rising incidence trends, global data on the incidence of pediatric psoriasis remain scarce.
Objective: To provide a comprehensive description of pediatric psoriasis incidence at the global, regional, and national levels.
Randomized trial to assess worsening renal function by adding dapagliflozin for acute decompensated heart failure.
ESC Heart Fail
January 2025
Division of Cardiology, Osaka Rosai Hospital, Osaka, Japan.
Aims: Dapagliflozin (DAPA), a sodium-glucose co-transporter 2 inhibitor, has been shown to reduce cardiovascular mortality among patients with chronic heart failure. We aimed to evaluate the impact on a worsening renal function (WRF) by adding DAPA as compared to standard decongestive therapy with loop diuretics alone.
Methods And Results: We enrolled 114 consecutive acute decompensated heart failure (ADHF) patients with a left ventricular ejection fraction (LVEF) of less than 50%.
Change in glucose, insulin and serum lipids due to ultra-processed food consumption in children with obesity.
Clin Obes
January 2025
Department of Epidemiology, Hésio Cordeiro Institute of Social Medicine, State University of Rio de Janeiro, Rio de Janeiro, Rio de Janeiro, Brazil.
While the association between ultra-processed food (UPF) consumption and chronic non-communicable diseases in adults is well-established, its relationship with serum markers of chronic diseases in children remains underexplored. This research investigates changes in serum markers in children with obesity during a trial aimed at reducing UPF consumption. The study is a prospective cohort, based on a parallel randomized controlled trial conducted between August 2018 and February 2020, with children aged 7-12 years.
View Article and Find Full Text PDFAims: Large-scale, real-world data on early initiation of sacubitril/valsartan in patients newly diagnosed (de novo) with HF with reduced ejection fraction (HFrEF) are limited. We examined the effectiveness of sacubitril/valsartan versus angiotensin-converting enzyme inhibitor (ACEi)/angiotensin receptor blocker (ARB) on all-cause and cause-specific hospitalizations among patients with de novo HFrEF from the Optum® dataset in the United States.
Methods: This retrospective cohort study included adult patients with de novo HFrEF (diagnosed ≤30 days) with left ventricular ejection fraction (LVEF) ≤40% who were first prescribed with sacubitril/valsartan or ACEi/ARB from 1 January 2016 to 31 March 2020.
Causes of hospitalization and mortality in persons with epilepsy: The EpiLink Bologna cohort, Italy.
Eur J Neurol
February 2025
Full Member of the European Reference Network for Rare and Complex Epilepsies (EpiCARE), IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy.
Background: Epilepsy significantly impacts on morbidity and mortality. Understanding hospitalization and mortality risks in persons with epilepsy (PWE) is essential for improving healthcare strategies. We aimed to investigate the risk and causes of hospitalization and mortality in PWE compared to a matched general population cohort.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!